ALSO NOTED: Glenmark buys Czech drug maker; Simcere files for IPO;and much more...

> Looking for a European beachhead for Europe's branded drug market, India's Glenmark has agreed to acquire a majority interest in the Czech drug company Medicamenta. Report

> China's generic drug maker Simcere Pharma has filed for a $120 million IPO. Report

> Alexza Pharmaceuticals says that mid-stage trials of its inhalable schizophrenia and migraine drug demonstrated positive results. AZ-004 demonstrated reduced agitation in schizophrenia patients while all three doses of AZ-001 reduced migraine pain in two hours compared to a placebo. Release

> Israel's BioLineRx has signed in-license agreements to develop and commercialize two new therapeutic candidates: BL-3040, a small molecule for the treatment of estrogen-regulated malignancies and osteoporosis; and BL-3050, a protein complex for the treatment of atherosclerosis. Release

> Endocyte, a biotech developing treatments for cancer and autoimmune diseases, announced Friday that it has completed a $15 million round of venture financing. Release

And Finally... Germany and Italy have joined a growing list of European countries recommending the universal use of the HPV vaccine Gardasil for girls aged 12 to 17. Report

Suggested Articles

The clamor for more transparency from the leading pandemic vaccine contenders has been getting louder.

The role gives one of the driving forces behind Bristol Myers Squibb’s $74 billion takeover of Celgene the chance to help build biotechs.

The appointment gives Sino-American biotech Brii the experience of a man who helped Gilead launch eight drugs in China in quick succession.